Exercise News and Research

Latest Exercise News and Research

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

AETNA's nutrition program to counter childhood obesity

Aetna Better Health, formerly Aetna Medicaid and CHIP Services, today announced an eight-week nutrition and exercise program for children at the North Fort Worth Branch of the Boys and Girls Clubs of Greater Fort Worth. The pilot program, named ACTIVATE Kids, was created to educate children on the risks of childhood obesity.

26 Sep 2009

Meta Health Services to raise $250,000 for general working capital

Meta Health Services Inc. (TSX-V: MHS.H) is pleased to announce that, subject to regulatory and shareholder approval, it will conduct a non-brokered private placement of up to 50,000,000 units at a price of $0.005 per unit, for gross proceeds of up to $250,000.

26 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009

Accelr8 Technology concludes technical development project with Becton

Accelr8 Technology Corporation announced today that it has concluded a technical development project with Becton, Dickinson and Company (“BD”) (NYSE: BDX).

26 Sep 2009

Intervention program helps children live healthier lives: Study

A new Iowa State University study found that a family, school and community intervention program helps children live healthier lives and could be a new tool in the fight against the nation's childhood obesity epidemic.

26 Sep 2009

Research study sheds light on mechanisms of pain alteration in infancy and adolescence

Scientists at Georgia State University have uncovered the mechanisms of how pain in infancy alters how the brain processes pain in adulthood.

26 Sep 2009

URMC study provides a new focus on health care in young adulthood

When adolescents graduate to young adulthood, their preventive care tends to fall by the wayside. A recent study has found that young adults are much less likely to use ambulatory or preventive care, even though their mortality rate is more than twice that of adolescents.

25 Sep 2009

Fourth-quarter and fiscal year end 2009 results announced by Noveko International

Noveko International Inc. ("the Company") today announces the financial results for its fourth quarter and fiscal year ended June 30, 2009.

25 Sep 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

ACP releases paper promoting increased funding for FDA

A new policy paper that calls for broader authority and increased funding for the Food and Drug Administration (FDA) was released today by the American College of Physicians (ACP). Improving FDA Regulation of Prescription Drugs offers a half-dozen recommendations about how to improve the agency's ability to approve and monitor new drugs.

25 Sep 2009

Lifestyle choices affect the incidence and treatment of cancer

There is clear evidence that lifestyle choices affect the incidence and treatment of cancer, according to a study published in the current issue of American Journal of Lifestyle Medicine (AJLM).

25 Sep 2009

FA announces their Second Annual Fellowship Convention dates

Food Addicts in Recovery Anonymous (FA) announces their Second Annual Fellowship Convention to be held at the Santa Clara Marriot from October 16-18, 2009 in Santa Clara, California.

25 Sep 2009

Contribution of psychological characteristics to weight loss

Being too optimistic could harm weight loss efforts. Research published in BioMed Central's open access journal, BioPsychoSocial Medicine, reveals the psychological characteristics that may contribute to weight loss.

25 Sep 2009

SXC Health Solutions raises $203.3 million from public offering of its common shares

SXC Health Solutions Corp. ("SXC" or the "Company") (NASDAQ: SXCI, TSX: SXC) announced today that it successfully completed its previously announced public offering of 5,175,000 of its common shares at a price to the public of $41.50 per share, which includes 675,000 shares sold pursuant to the exercise of the underwriters' over-allotment option.

24 Sep 2009

Opexa Therapeutics' endeavor in the field of stem cell technology

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company’s recently announced exclusive stem cell agreement with Novartis, one of the world’s largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

24 Sep 2009

Enrollment for pSivida's pilot FAVOR clinical study commences

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien in patients with macular edema secondary to retinal vein occlusion.

24 Sep 2009

Handheld diabetic test from MSGI's Nanobeak

MSGI Security Solutions Inc. (OTCBB: MSGI) today reported that the Company is launching its first product derived from NASA technology, a handheld test for Diabetes, which uses breath instead of blood.

24 Sep 2009

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

MACH II clinical trial results revealed

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced new clinical data from Academic Medical Center’s (AMC) three-year follow-up results from patients in the Impella 2.5 arm of the MACH II trial, revealing improved left ventricular function, cardiac output and quality of life.

24 Sep 2009